CA2012875C - Skin permeation enhancer compositions - Google Patents
Skin permeation enhancer compositionsInfo
- Publication number
- CA2012875C CA2012875C CA002012875A CA2012875A CA2012875C CA 2012875 C CA2012875 C CA 2012875C CA 002012875 A CA002012875 A CA 002012875A CA 2012875 A CA2012875 A CA 2012875A CA 2012875 C CA2012875 C CA 2012875C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- skin
- pharmacologically active
- active agent
- ether
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
Abstract
Skin permeation enhancer compositions are provided which increase the permeability of skin to transdermally administered pharmacologically active agents. The composition contains diethylene glycol monoethyl or monomethyl ether in addition to an ester component such as propylene glycol monolaurate, methyl laurate or the like. The compositions are particularly useful in conjunction with the transdermal administration of steroid drugs such as progestogens and estrogens.
Methods and drug delivery systems for using the enhancer compositions are provided as well.
Methods and drug delivery systems for using the enhancer compositions are provided as well.
Description
l t~
20 ~ 2 ~75 SKIN PERMEATION ENHANCER COMPOSITIONS
Description Technical Field This invention relates generally to the transdermal administration of pharmacologically active agents and more particularly relates to methods and compositions for enhancing the permeability of the skin to such agents.
Backqround The delivery of drugs through the skin provides many advantages; primarily, such a means of delivery is a comfortable, convenient and noninvasive way of administering drugs. The variable rates of absorption and metabolism encountered in oral treatment are avoided, and other inherent inconveniences -- e.g., gastrointestinal irritation and the like -- are eliminated as well. Transdermal drug delivery also makes possible a high degree of control over blood concentrations of any particular drug.
Skin is a structurally complex, relatively thick membrane. Molecules moving from the environment into and through intact skin must first penetrate the stratum-corneum and any material on its surface. They must then penetrate the viable epidermis, the papillary dermis, and the capillary walls into the blood stream or lymph channels. To be so absorbed, molecules must overcome a different resistance to penetration in each type of tissue. Transport across the skin membrane is thus a complex phenomenon. However, it is the cells of the stratum corneum which present the primary barrier to absorption of topical compositions or transdermally administered drugs. The stratum corneum is a thin layer of dense, highly keratinized cells approximately 10-15 microns thick over most of the body. It is believed to be the high degree of keratinization within these cells as well as their dense packing which creates in most cases a substantially impermeable barrier to drug penetration.
In order to increase skin permeability, and in particular to increase the permeability of the stratum corneum (i.e., so as to achieve enhanced penetration, through the skin, of the drug to be administered transdermally), the skin may be pretreated with a penetration enhancing agent (or "permeation enhancer", as sometimes referred to herein) prior to application of a drug. Alternatively, and preferably, a drug and a permeation enhancer are concurrently delivered.
The present invention is directed to a novel composition for enhancing the penetration of pharmacologically active agents through skin, the composition in a preferred embodiment comprising a combination of diethylene glycol monoethyl ether (available under the trademark Tran~cutol from Gattefosse; sometimes referred to herein as "TC") with at least one long-chain ester, e.g., of lauric acid, including glycerol monolaurate ("GML"), propylene glycol monolaurate ("PGML"), propylene glycol dilaurate ("PGDL"~, methyl laurate ("ML"), ethyl laurate ("EL"), or the like. Surprisingly, this combination has been found by the inventor herein to be more effective in enhancing the penetration of pharmacologically active agents through skin than either Transcutol or a lauric acid ester alone. The novel enhancer composition is _3_ 201287~
particularly effective in conjunction with the transdermal administration of steroid drugs.
While there are a number of patents and publications available which relate to the transdermal administration of steroid drugs, to the use of Transcutol as a skin permeation enhancer, and to combination-type enhancer compositions, applicant is unaware of any art which relates to the "combination"
enhancer composition disclosed and claimed herein or to the use of such an enhancer composition with a steroid drug.
Description of the Prior Art Skin permeation enhancers: Various compounds for enhancing the permeability of skin are known in the art. U.S. Patent Nos. 4,006,218, 3,551,554 and 3,472,931, for example, respectively describe the use of dimethylsulfoxide (DMSO), dimethyl formamide (DMF) and N,N-dimethylacetamide (DMA) to enhance the absorption of pharmacologically active agents through the stratum corneum. Other compounds which have been used to enhance skin permeability include: decylmethylsulfoxide (CloMSO); Transcutol, cited in the preceding section;
polyethylene glycol monolaurate (PEGML; see, e.g., U.S.
Patent No. 4,568,343); glycerol monolaurate (U.S. Patent No. 4,746,515); propylene glycol monolaurate (see European Patent Application No. 87402945.7, Published as EP Publication No. 272 987, which derives from U.S.
Patent Application Serial No. 945,356, filed 22 December 1986, of common assignment herewith); ethanol (e.g., as in U.S. Patent No. g,379,454); eucalyptol (U.S. Patent No. 4,440,777); lecithin (U.S. Patent No. 4,783,450);
the l-substituted azacycloheptan-2-ones, particularly l-n-dodecylcyclazacycloheptan-2-one (available under the trademark Azone~ from Nelson Research & Development Co., Irvine, CA; see U.S. Patent Nos. 3,989,816, 4,316,893, 2012~75 4,405,616 and 4,557,934); propylene glycol in combination with a fatty acid such as linoleic acid (Europrean Patent Publication No. 261429); "cell envelope disordering compounds" such as methyl laurate or oleic acid in combination with N-(hydroxyethyl) pyrrolidone (U.S. Patent No. 4,537,776) or C3 - C4 diols (U.S. Patent No. 4,552,872, European Patent Application Publication No. 043738). U.S. Patent No. 4,764,379 discloses a binary enhancer composition of ethanol and glycerol monolaurate.
Transdermal administration of steroid drugs:
U.S. Patent Nos. 4,379,454, 4,460,372, 4,559,222, 4,568,343 (cited above with respect to the use of PEGML
as a permeation enhancer) and European Patent Publication No. 285563 relate to the transdermal administration of estrogens, while U.S. Patent No.
4,435,180 provides an example (Example IV at col. 7) which describes a system for the transdermal administration of progesterone. Concurrent administration of progesterone and estradiol esters is described in U.S. Patent No. 4,788,062. PCT Publication WO88/01496 and European Patent Publication No. 275716 both describe transdermal administration of a composition containing both an estrogen and a progestogen. In addition, European Patent Publication No. 235090 relates to the transdermal administration of an ethinyl estradiol/norethindrone acetate composition, while European Patent Publication No. 279982 describes a transdermal delivery system for the concurrent administration of ethinyl estradiol and levonorgestrel.
U.S. Patent No. 4,746,515, cited above as describing the use of GML as a permeation enhancer, also relates to the transdermal administration of steroid drugs. U.S.
Patent No. 4,704,282 relates to a transdermal drug delivery system for the administration of progesterone, testosterone and hydrocortisone. Other patents which relate to transdermal drug delivery devices stated to be useful in the administration of steroid drugs include U.S. Patent Nos.: 3,598,122; 3,598,123; 3,731,683;
3,797,494; 3,854,480; 3,923,939; 3,926,188; 3,964,482;
and 4,717,568.
Disclosure of the Invention Accordingly, it is an object of the present invention to provide a skin permeation enhancer composition comprising a first component that is an ether selected from the group consisting of diethylene glycol monoethyl ether and diethylene glycol monomethyl ether and a second component that is an ester given by the formula [CH3(CH2)mCOO]nR, in which m is an integer from 8 to 16, preferably 8 to 12, most preferably 10, n is 1 or 2, preferably 1, and R is a lower alkyl (Cl-C3) residue which may or may not be substituted with 1 or 2 hydroxyl groups.
It is another object of the present invention to provide a composition of matter useful for the delivery of a pharmacologically active agent through skin, comprising the above-described enhancer composition in combination with a selected pharmacologically active agent.
It is still another object of the invention to provide such a composition in which the pharmacologically active agent is a steroid drug.
It is a further object of the invention to provide methods and transdermal delivery systems for using the aforementioned compositions.
Additional objects, advantages and novel features of the invention will be set forth in part in the description which follows, and in part will become apparent to those skilled in the art upon examination of the following, or may be learned by practice of the invention.
In one aspect of the invention, a composition of matter is provided that is useful for the delivery of a pharmacologically active agent through the skin, comprising:
(a) a therapeutically effective amount of the at least one pharmacologically active agent; and (b) an amount of a permeation enhancer composition effective to enhance the penetration of the at least one pharmacologically active agent through skin, the enhancer composition comprising an ether component selected from the group consisting of diethylene glycol monoethyl ether and diethylene glycol monomethyl ether, and an ester component given by the formula ~CH3(CH2)mCOO]nR, in which m is an integer from 8 to 16, n is 1 or 2, and R is a lower alkyl (Cl-C3) residue which is either unsubstituted or substituted with one or two hydroxyl groups.
In another aspect of the invention, a method is provided that is useful for enhancing the skin penetration of a pharmacologically active agent, comprising applying to the skin, in addition to a therapeutically effective amount of the pharmacologically active agent, a permeation enhancer composition comprising an ether component selected from the group consisting of diethylene glycol monoethyl ether and diethylene glycol monomethyl ether, and an ester component given by the formula ~CH3(CH2)mCOO]nR, in which m, n and R are as defined above.
In still another aspect of the invention, a system is provided useful for the transdermal administration of a pharmacologically active agent, comprising:
(a) a source of the pharmacologically active agent;
(b) a source of a permeation enhancer composition comprising an ether component selected from 201287~
the group consisting of diethylene glycol monoethyl ether and diethylene glycol monomethyl ether, and an ester component given by the formula [CH3(CH2)mCOO]nR
with m, n and R as defined above; and S (c) a means for maintaining the system in agent and enhancer composition transmitting relationship to the skin.
Brief Description of the Fiqure Figure 1 is a graphic representation of the composition optimization results obtained in Example 6.
Modes for Carryinq Out the Invention "Penetration enhancement" or "permeation enhancement" as used herein relates to an increase in the permeability of skin to a pharmacologically active agent, i.e., so as to increase the rate at which the drug permeates through the skin and enters the bloodstream. The enhanced permeation effected through the use of such enhancers, and, in particular, through the use of the enhancer composition of the present invention, can be observed by measuring the rate of diffusion of drug through animal or human skin using a diffusion cell apparatus as described in the Examples herein By "transdermal" delivery, applicants intend to include both transdermal (or "percutaneous") and transmucosal administration, i.e., delivery by passage of a drug through the skin or mucosal tissue and into the bloodstream.
"Carriers" or "vehicles" as used herein refer to carrier materials suitable for transdermal drug administration, and include any such materials known in the art, e.g., any liquid, gel, solvent, liquid diluent, solubilizer, or the like, which is nontoxic and which does not interact with other components of the composition in a deleterious manner. Examples of suitable carriers for use herein include water, mineral oil, silicone, liquid sugars, waxes, petroleum jelly, and a variety of other oils and polymeric materials. In addition, one or both of the components of the present enhancer composition may also serve as a carrier.
By the term "pharmacologically active agent"
or "drug" as used herein is meant any chemical material or compound suitable for transdermal or transmucosal administration which induces a desired systemic effect.
Such substances include the broad classes of compounds normally delivered through body surfaces and membranes, including skin. In general, this includes: anti-infectives such as antibiotics and antiviral agents;
analgesics and analgesic combinations; anorexics;
antihelminthics; antiarthritics; antiasthmatic agents;
anticonvulsants; antidepressants; antidiabetic agents;
antidiarrheals; antihistamines; antiinflammatory agents;
antimigraine preparations; antinauseants;
antineoplastics; antiparkinsonism drugs; antipruritics;
antipsychotics; antipyretics; antispasmodics;
anticholinergics; sympathomimetics; xanthine deriva-tives; cardiovascular preparations including calcium channel blockers and beta-blockers such as pindolol and antiarrhythmics; antihypertensives; diuretics;
vasodilators including general coronary, peripheral and cerebral; central nervous system stimulants; cough and cold preparations, including decongestants; hormones such as estradiol and other steroids, including corticosteroids; hypnotics; immunosuppressives; muscle relaxants; parasympatholytics; psychostimulants;
sedatives; and tranquilizers.
Steroid drugs represent a preferred class of drugs for use in conjunction with the enhancer composition of the present invention. Examples of steroid drugs useful herein include: progestogens such 9 201287~
as norethindrone, norethindrone acetate, desogestrel, 3-keto desogestrel, gestadene and levonorgestrel estrogens such as estradiol and its esters, e.g., estradiol valerate, cyprionate, decanoate and acetate, as well as ethinyl estradiol; corticosteroids such as cortisone, hydrocortisone, fluocinolone acetonide; and testosterone. In a particularly preferred embodiment, the compositions of the invention include one or more estrogens as well as one or more progestogens.
By "therapeutically effective" amount of a pharmacologically active agent is meant a nontoxic but sufficient amount of a compound to provide the desired therapeutic effect. An "effective" amount of a permeation enhancer as used herein means an amount that will provide the desired increase in skin permeability and, correspondingly, the desired depth of penetration, rate of administration, and amount of drug delivered.
In a preferred embodiment, the enhancer composition of the invention contains a first, ether, component which is diethylene glycol monoethyl or monomethyl ether, and a second, ester, component given by the formula [CH3(CH2)mCOO]nR with m, n and R as defined above, wherein the preferred ratio (v/v) of the ether to the ester components in the enhancer composition ranges from about 90:10 to about 10:90, more preferably from about 90:10 to about 40:60. This ratio represents the relative amounts of the ether and ester components in the initial formulation of the enhancer composition. The preferred ratio may vary depending on whether-the enhancer composition is applied directly to the skin in an ointment, gel or the like, or whether it is incorporated into one or more layers of a transdermal drug delivery device. The preferred ratio may also vary with the specific components selected for the enhancer composition.
-lO- 20~87~
The ester component represented by the formula [CH3(CH2)mCOO]nR with m, n and R as above, contains 1 or 2, preferably 1, 10- to 18-carbon chains (i.e., wherein m is 8 to 16) bound to a central lower alkyl (Cl-C3) moiety which may be either unsubstituted or substituted with one or two hydroxyl groups. Thus, the component may include one or two capric, lauric, myristic, palmitic or stearic acid residues. In the preferred embodiment herein, the ester component is a lower alkyl (Cl-C3) laurate (i.e., m is 10 and n is 1), and in a particularly preferred case is "PGML". It will be appreciated by those skilled in the art that the commercially available material sold as "PGML" is typically a mixture of propylene glycol monolaurate itself, propylene glycol dilaurate, and either propylene glycol, methyl laurate, or both. Thus, the terms "PGML"
or "propylene glycol monolaurate" as used herein are intended to encompass both the pure compound as well as the mixture that is typically obtained commercially.
The present invention accordingly encompasses both the mixture of compounds which will typically be present in commercially available PGML, and as well as pure propylene glycol monolaurate itself.
In addition to the ester component, as noted above, the enhancer composition also contains diethylene glycol monoethyl or monomethyl ether, or both, preferably the monoethyl ether, i.e., Transcutol. While the ether and ester components have been sometimes referred to herein as the "first" and "second"
components, it will be appreciated by those skilled in the art that the composition may contain both the monoethyl and monomethyl ether, and may in addition include more than one ester component.
As will be established in the examples which follow, the combination of the ether and ester components increases the skin flux of a selected drug, generally, relative to the use of either type of component alone. (It should be noted, however, that the flux of a given drug through skin will vary with the drug or drugs selected for administration, the structure of the transdermal delivery device used, if any, and the vehicles incorporated into the drug-containing composition.) With certain drugs, one or both of the components may in addition act as a solubilizer or vehicle.
The composition may in addition include one or more selected carriers or excipients, and various agents and ingredients commonly employed in dermatological ointments and lotions. For examples, fragrances, opacifiers, preservatives, anti-oxidants, gelling agents, perfumes, thickening agents, stabilizers, surfactants, emollients, coloring agents, and the like may be present.
The relative amounts of the components in these compositions can vary a great deal. For example, the amount of drug or drugs present in the composition will depend on a variety of factors, including the disease to be treated, the nature and activity of the drug, the desired effect, possible adverse reactions, the ability and speed of the drug to reach its intended target, and other factors within the particular knowledge of the patient and physician. The amount of enhancer present in the composition will similarly depend on a number of factors, e.g., on the depth of cutaneous penetration desired, the strength of the particular enhancer, on the specific drug or drugs selected, and the like.
The method of delivery of the present compositions may also vary, but necessarily involves applying the selected composition to a defined surface of the skin or other tissue for a period of time sufficient to provide the desired blood level of drug for the desired period of time. The method may involve direct application of the composition as an ointment, gel, cream, or the like, or may involve use of a drug delivery device as taught, for example, in U.S. Patent Nos. 3,742,951, 3,797,494 or 4,568,343, and in commonly assigned U.S. Patent Application Serial No. 945,356, cited supra.
A transdermal delivery system can be constructed with the enhancer composition described hereinabove to deliver drugs for sustained drug delivery. The targeted skin flux for delivery of a particular drug can be achieved by adjusting vehicle composition and vehicle loading, as well as by adjusting the surface area through which the compositions are administered to skin.
Preferred transdermal drug delivery systems for use herein contain one or more drug/permeation enhancer reservoirs, a backing layer, and optionally one or more additional layers as those skilled in the art of transdermal drug delivery will readily appreciate.
The drug/permeation enhancer reservoir(s) will typically be in the the form of a matrix comprising rubber or other polymeric material, e.g., natural and synthetic rubbers such as polybutylene, polyisobutylene, polybutadiene, polyethylene, styrene-butadiene copolymers, polyisoprene, polyurethane, copolyesters, ethylene/acrylic copolymers, polyether amides, silicones and their copolymers, and butadiene/acrylonitrile copolymers, ethylene vinyl acetate, gelled or thickened mineral-oil, petroleum jelly and various aqueous gels and hydrophilic polymers that may serve as thickening agents. The matrix is applied to skin using a suitable adhesive as described, for example, in U.S. Patent No.
4,568,343, supra. In some cases, the matrix may itself be comprised of an adhesive material.
The drug reservoir layer is formulated so as to contain the selected pharmacologically active agent(s) as well as the above enhancer composition. In a preferred embodiment, the layer will contain up to about 15 wt.% drug (e.g., 5 wt.% estrogen, 10 wt.%
progestogen, in a preferred contraceptive patch), 5-40 wt.% enhancer composition, e.g., an 80:20 v/v Transcutol/PGML admixture, and up to 4 wt.% silicone oil or mineral oil to serve as a tackifier for the pressure-sensitive adhesive. The pressure sensitive adhesive which serves as the reservoir for this mixture is typically a polyisobutylene, silicone or acrylate adhesive. The layer may be formulated so that the selected drug is contained therein below saturation, at saturation, or in excess.
The backing membrane, which may be either occlusive or nonocclusive, is preferably comprised of a flexible, stretchable, polymer film, e.g., of polyether urethane, polyester urethane, polyamide, or other related copolymers. The material and thickness selected for the backing membrane is preferably such that a transdermal system can be provided having good wearability for at least a seven-day application.
It is to be understood that while the invention has been described in conjunction with the preferred specific embodiments thereof, that the foregoing description as well as the examples which follow are intended to illustrate and not limit the scope of the invention. Other aspects, advantages and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.
-14- 2~1287~
Example 1 In vitro Franz flow-through cells were used to compare the penetration of estradiol through skin using different ratios of Transcutol and methyl laurate. A
piece of human cadaver skin was mounted between the two half-cells and fastened with a clamp. Two hundred ~1 of saturated estradiol solutions (prepared with different ratios of Transcutol and methyl laurate, as indicated in Table 1) were applied to the donor compartment to start the experiment. The receiver compartment was filled with 0.1% gentamicin in distilled, deionized water and the temperature was maintained at 32~C. Samples were taken at preset time intervals and assayed by HPLC. The flux was calculated from the slope of the cumulative amounts of estradiol in the receiver compartment vs.
time. The results are summarized in Table 1. An increase in skin flux was observed when Transcutol was used in combination with methyl laurate at different ratios. The maximum flux (0.71 ~g/cm2/hr) was achieved when the ratio of Transcutol: methyl laurate was 80:20 (v/v) as compared to 0.36 and 0.35 ~g/cm2/hr when Transcutol or methyl laurate, respectively, were used alone.
201287~
Table 1 The effect of binary solutions with Transcutol and methyl laurate on the penetration of 5estradiol through human cadaver skin Vehicle composition Flux ( llg/cm2/hr ) Transcutol 0.35 + 0.19 Transcutol:methyl laurate0.71 i 0.03 (80:20, v/v) Transcutol:methyl laurate0.59 ~ 0.12 (60:gO, v/v) Transcutol:methyl laurate0.47 i 0.05 (40:60, v/v) Transcutol:methyl laurate0.46 i 0.14 (20:80, v/v) methyl laurate 0.36 + 0.16 The experiments were performed in triplicate for each vehicle combination.
20128~5 Example 2 The in vitro Franz flow-through cells were used to compare the penetration of estradiol through skin using different ratios of Transcutol in commercial PGML
(obtained from Gattefosse; approximate composition of this "PGML" was determined to be about 50 wt.% propylene glycol monolaurate itself, 40-45 wt.% propylene glycol dilaurate, and 5-10 wt.% propylene glycol). A piece of human cadaver skin was mounted between the two half-cells and fastened with a clamp. Two hundred ~1 of saturated estradiol solutions (prepared with different ratios of Transcutol and propylene glycol monolaurate, as indicated in Table 2) were applied to the donor compartment to start the experiment. The receiver compartment was filled with 0.1% gentamicin in distilled, deionized water and the temperature was maintained at 32~C. Samples were taken at preset time intervals and assayed by HPLC. The flux was calculated from the slope of the cumulative amounts of estradiol in the receiver compartment vs. time. The results are summarized in Table 2. The skin fluxes increase 2-3 fold when Transcutol was used in combination with propylene glycol monolaurate at different ratios. The flux reached a maximum value of 0.69 ~g/cm2/hr, when the ratio of Transcutol to PGML was about 80:20 (v/v). By contrast, fluxes of 0.37 and 0.21 ~g/cm2/hr were obtained for propylene glycol monolaurate and Transcutol, respectively, used alone.
Table 2 The effect of binary solutions with Transcutol and propylene glycol monolaurate on the penetration of estradiol through human cadaver skin Vehicle composition Flux ( ~lg/cm2/hr ) Transcutol 0.21 ~ 0.16 Transcutol:propylene glycol 0.69 + 0.12 monolaurate (80:20, v/v) Transcutol:propylene glycol 0.63 + 0.21 monolaurate (60:40, v/v) Transcutol:propylene glycol 0,49 i 0.14 monolaurate (40:60, v/v) Transcutol:propylene glycol 0.40 + 0.13 monolaurate (20:80, v/v) propylene glycol monolaurate 0.37 ~ 0.14 The experiments were performed in triplicate for each vehicle combination.
Example 3 The in vitro Franz flow-through cells were used to compare the penetration of norethindrone, norethindrone acetate and levonorgesterol in vehicles having different ratios of Transcutol and methyl laurate. A piece of human cadaver skin was mounted between the two half-cells and fastened with a clamp. Two hundred ~1 of saturated progestogens in solutions (prepared having different ratios of Transcutol and methyl laurate, as indicated in Table 3) were applied to the donor compartment to start the experiment. The receiver compartment was filled with 0.1% gentamycin in distilled, deionized water and the temperature was maintained at 32~C. Samples were taken at preset time interval and assayed by HPLC. The flux was calculated from the slope of the cumulative amounts of progestogens in the receiver compartment vs. time.
The skin fluxes for norethindrone, norethindrone acetate and levonorgesterol from vehicles with different ratios of Transcutol and methyl laurate are summarized in Table 3. The same trend, i.e., an increase in flux when Transcutol was used in combination with methyl laurate, was observed for these three progestogens. The maximum flux was again observed when the ratio of Transcutol to methyl laurate was about 80:20 (v/v). The maximum flux values obtained were 1.55, 1.71 and 0.25 ~g/cm2/hr for norethindrone, norethindrone acetate and levonorgesterol, respectively. In comparison, the fluxes for norethindrone, norethindrone acetate and levonorgesterol, with Transcutol alone, were 0.26, 0.63 and 0.09 ~g/cm2/hr, respectively, and, for methyl laurate alone, were 0.60, 1.03 and 0.12 ~g/cm2/hr. (It should also be noted that the 60:40 formulations gave slightly lower fluxes than for the 80:20 formulations, but were higher than that of either methyl laurate or Transcutol alone.) -lg- 201287 a a ~ ' O o o o o o ~ 1 o o o o o o ~ o ~ ,~, ,~ ~ ~
c ~'~ ~ ~ ~ ~ ~ ~ ~
~ L
~ a~
c C
E ~ ~ O _1 o --~ ~ ~ O O O O O O
,C ~ ~ ~+l +l ~ ~ ~ E
1 5 R 3 r ~ X ~ q u ~ C, Lo :-C O , U
c ~ . , o o o o o o o ~ ; ~ ~ ~ a u O ~~ ~D ~ ~1 ~J ~ I ~ ~ ~ . .
~, ~ o ~ l o o o a c Ll a o c a a ~ ~ e ~ o Ll Ll Ll Ll ~I
r 4I ~ I ~
v cc c c E e ~E ~E ~ E
o ~ ~C~
a u o o o u o ~ 4 ~ O O ~ O ~ O
Example 4 The in vitro Franz flow-through cells were used to compare the penetration of norethindrone, norethindrone acetate and levonorgesterol in vehicles containing varying amounts of Transcutol and propylene glycol mono-laurate. A piece of human cadaver skin was mounted between the two half-cells and fastened with a clamp.
Two hundred ~1 of saturated progestogen solutions (having varying ratios of Transcutol and propylene glycol monolaurate, as indicated in Table 4) were applied to the donor compartment to start the experi-ment. The receiver compartment was filled with 0.1%
gentamicin in distilled, deionized water and the temper-ature was maintained at 32~C. Samples were taken at preset time interval and assayed by HPLC. The flux was calculated from the slope of the cumulative amounts of progestogens in the receiver compartment vs. time.
The skin fluxes for norethindrone, norethindrone acetate and levonorgesterol from different ratios of Transcutol and PGML are summarized in Table 4. The same trend, i.e., increases in skin flux when Transcutol was used in combination with PGML, was observed for all three progestogens. The maximum flux for norethindrone was 0.79 ~g/cm2/hr, was observed when Transcutol was combined with propylene glycol monolaurate in an 80:20 (v/v) ratio, as compared to 0.17 and 0.31 for Transcutol and PGML alone, respectively. The maximum fluxes for norethindrone acetate were 1.31 to 1.33 ~g/cm2/hr when Transcutol was combined with PGML in 80:20 and 60:40 (v/v) ratios as compared to 0.26 and 0.39 for Transcutol and PGML alone. Similarly, the fluxes for levonorges-terol ranged from 0.06 to 0.09 ~g/cm2/hr when Transcutol was used in combination with PGML; the maximum flux was observed at a Transcutol:PGML ratio of 40:60 (v/v). By contrast, the fluxes, for levonorgesterol, were 0.02 and 0.06, respectively, using Transcutol and PGML alone.
--21 2 0 1 2 g 7 rj O ~ o o o o o o o o o o o o o o o o o o o o o o w - o c~ v _, o ,.
G ~
v a ~ L LJ ,, ~ ~ E a ~ o.
. u _~ ~ o ~ o o ._ o o o o o o C ~ ~
" ~ a ~ ~ x~ ~ ~ v ~" o, ~ , o ~ ~ o o ,~
O v ¢ O c ~' a ~ Z
,-, c n o ' f a u ~ . c O a~
,fa ,1 ~ ~ o O, O O O O
~, O , , ~
~- ~ L ~ a~ 1 U
O ~, ' t~ ~f,~ ~ ,,~ _ U tU ~ ~ ~ ~ ~ ~ ~
V " O
2 5 LV o I , C
U U U U E
~, ~ ~ ~ ~ O
~a~ v a c a c ~ c a a o ~ a ~ v u,o c o o c u o CL 8 ~ 8 r ~ .~ c --O O O O _1 ro ' o o o ~o' -22- 2~1 2~75 Example 5 A series of norethindrone acetate delivery systems was prepared by the following procedures. 2% of the norethindrone acetate (NA) was mixed and sonicated with various ratios of TC and PGML for 10 minutes.
Appropriate amounts of the drug-enhancer mixture were then added into a solution of silicone adhesive polymer (Dow Corning silicone #2675) in freon (50 wt.%) and rotated overnight. The drug-enhancer-polymer mixture was then cast on a polyester film (#1022 release liner) with a 8 mil knife. The solvent in the polymer system was evaporated in a 75~C oven for 15 min. The resulting polymer film was laminated with another polyester film (#1022).
Franz flow-through cells were used for in vitro skin flux experiments. The release liners were removed, and the polymer systems made were then laminated on stratum corneum of the human cadaver skin and mounted between the two half-cells and fastened with a clamp.
The receiver compartment was filled with 0.1% gentamicin in distilled, deionized water. The temperature was maintained at 32~C. Samples were taken every 8 hours for 3 days and assayed by HPLC. The flux was calculated from the slope of the cumulative amounts of norethindrone acetate in the receiver compartment vs.
time. The results of skin flux of norethindrone acetate in these polymer systems were tabulated in Table 5. The flux of norethindrone acetate from polymer systems was increased when Transcutol was used in combination with PGML, relative to Transcutol alone. The norethindrone acetate flux can also be increased by enhancer loading.
The flux increased from 0.17 to 0.75 ~g/cm2/hr when 20%
Transcutol/PGML (80:20, v/v) was incorporated into the polymer system instead of 5%. The flux was increased from 0.29 to 0.45 when 20% of the mixture was incorporated into the polymer instead of 5%.
Table 5 Flux of norethindrone acetate from a polymer matrix through human cadaver skin Vehicle Ratio Flux incorporated (NA:Vehicle:Sil.) (~g/cm2hr) TC 2:10:88 0.15 i 0.01 TC:PGML (80:20) 2:5:93 0.17 i 0.02 TC:PGML (80:20) 2:20:78 0.75 i 0.07 TC:PGML (50:50) 2:10:88 0.32 i 0.05 TC:PGML (20:80) 2:5:93 0.29 i 0.05 TC:PGML (20:80) 2:20:78 0.45 i 0.08 PGML 2:10:88 0.42 i 0.03 *Average i standard deviation; three experiments were performed for each vehicle combination.
-24- 201287~
Example 6 Optimization of the Transcutol/PGML Ratio: This study was designed as a matrix formulation step. It was conducted using Dow Corning silicone polymer #2675 as the matrix contact adhesive in which estradiol and TC/PGML were dispersed, with varying ratios of TC to PGML. The formulations tested are represented in Table 6.
Table 6 TC/PGML Enhancer Silicone Estradiol Ratio (v/v) (wt.%) (wt.%) (wt.%) 80:20 81 5 60:40 14% 81 5 40:60 81 5 80:20 75 5 60:40 20% 75 5 40:60 75 5 Methodoloqy: General in vitro skin methodology was as described in the preceding examples.
Skin permeation conditions: temperature, 32~C;
sampling times 7h, 17h, 24h, 48h; n=4. A static vertical Franz cell was used.
Skin preparation: pieces of skin recently excised (aesthetic surgery) prepared according to the method of Kligman.
Assay procedure: estradiol in the receptor compartment was assayed using HPLC at 210 nm using acetonitrile/TEAP buffer, pH 3.
Data analysis: estradiol skin fluxes were calculated by dividing the total amount of E2 permeated by the total duration of the experiment.
Matrices: matrices studied were fabricated with a hand-casting/solvent drying/hand-laminating general process. All matrices were allowed to equilibrate 8-10 days before skin permeation testing was begun.
Results and Discussion: The E2 skin flux values obtained with the different matrices are represented in Figure 1. The E2 fluxes were in the range of 0.06-0.2 ~g/cm2/hr for the different matrices tested. In a general way, the 20% loading gave higher fluxes than the 14% loading. For the two E2 loadings, 14% and 20%, there was a significant increase in E2 flux as the TC/PGML ratio decreased. With 14% loading, the highest flux was obtained with a TC/PGML ratio of 40:60, while with 20% loading, the highest flux was obtained with a TC/PGML ratio of 60:40.
This study permits one to conclude that the TC/PGML ratio should be optimized when the drug/enhancer composition is dispersed in a polymer medium.
20 ~ 2 ~75 SKIN PERMEATION ENHANCER COMPOSITIONS
Description Technical Field This invention relates generally to the transdermal administration of pharmacologically active agents and more particularly relates to methods and compositions for enhancing the permeability of the skin to such agents.
Backqround The delivery of drugs through the skin provides many advantages; primarily, such a means of delivery is a comfortable, convenient and noninvasive way of administering drugs. The variable rates of absorption and metabolism encountered in oral treatment are avoided, and other inherent inconveniences -- e.g., gastrointestinal irritation and the like -- are eliminated as well. Transdermal drug delivery also makes possible a high degree of control over blood concentrations of any particular drug.
Skin is a structurally complex, relatively thick membrane. Molecules moving from the environment into and through intact skin must first penetrate the stratum-corneum and any material on its surface. They must then penetrate the viable epidermis, the papillary dermis, and the capillary walls into the blood stream or lymph channels. To be so absorbed, molecules must overcome a different resistance to penetration in each type of tissue. Transport across the skin membrane is thus a complex phenomenon. However, it is the cells of the stratum corneum which present the primary barrier to absorption of topical compositions or transdermally administered drugs. The stratum corneum is a thin layer of dense, highly keratinized cells approximately 10-15 microns thick over most of the body. It is believed to be the high degree of keratinization within these cells as well as their dense packing which creates in most cases a substantially impermeable barrier to drug penetration.
In order to increase skin permeability, and in particular to increase the permeability of the stratum corneum (i.e., so as to achieve enhanced penetration, through the skin, of the drug to be administered transdermally), the skin may be pretreated with a penetration enhancing agent (or "permeation enhancer", as sometimes referred to herein) prior to application of a drug. Alternatively, and preferably, a drug and a permeation enhancer are concurrently delivered.
The present invention is directed to a novel composition for enhancing the penetration of pharmacologically active agents through skin, the composition in a preferred embodiment comprising a combination of diethylene glycol monoethyl ether (available under the trademark Tran~cutol from Gattefosse; sometimes referred to herein as "TC") with at least one long-chain ester, e.g., of lauric acid, including glycerol monolaurate ("GML"), propylene glycol monolaurate ("PGML"), propylene glycol dilaurate ("PGDL"~, methyl laurate ("ML"), ethyl laurate ("EL"), or the like. Surprisingly, this combination has been found by the inventor herein to be more effective in enhancing the penetration of pharmacologically active agents through skin than either Transcutol or a lauric acid ester alone. The novel enhancer composition is _3_ 201287~
particularly effective in conjunction with the transdermal administration of steroid drugs.
While there are a number of patents and publications available which relate to the transdermal administration of steroid drugs, to the use of Transcutol as a skin permeation enhancer, and to combination-type enhancer compositions, applicant is unaware of any art which relates to the "combination"
enhancer composition disclosed and claimed herein or to the use of such an enhancer composition with a steroid drug.
Description of the Prior Art Skin permeation enhancers: Various compounds for enhancing the permeability of skin are known in the art. U.S. Patent Nos. 4,006,218, 3,551,554 and 3,472,931, for example, respectively describe the use of dimethylsulfoxide (DMSO), dimethyl formamide (DMF) and N,N-dimethylacetamide (DMA) to enhance the absorption of pharmacologically active agents through the stratum corneum. Other compounds which have been used to enhance skin permeability include: decylmethylsulfoxide (CloMSO); Transcutol, cited in the preceding section;
polyethylene glycol monolaurate (PEGML; see, e.g., U.S.
Patent No. 4,568,343); glycerol monolaurate (U.S. Patent No. 4,746,515); propylene glycol monolaurate (see European Patent Application No. 87402945.7, Published as EP Publication No. 272 987, which derives from U.S.
Patent Application Serial No. 945,356, filed 22 December 1986, of common assignment herewith); ethanol (e.g., as in U.S. Patent No. g,379,454); eucalyptol (U.S. Patent No. 4,440,777); lecithin (U.S. Patent No. 4,783,450);
the l-substituted azacycloheptan-2-ones, particularly l-n-dodecylcyclazacycloheptan-2-one (available under the trademark Azone~ from Nelson Research & Development Co., Irvine, CA; see U.S. Patent Nos. 3,989,816, 4,316,893, 2012~75 4,405,616 and 4,557,934); propylene glycol in combination with a fatty acid such as linoleic acid (Europrean Patent Publication No. 261429); "cell envelope disordering compounds" such as methyl laurate or oleic acid in combination with N-(hydroxyethyl) pyrrolidone (U.S. Patent No. 4,537,776) or C3 - C4 diols (U.S. Patent No. 4,552,872, European Patent Application Publication No. 043738). U.S. Patent No. 4,764,379 discloses a binary enhancer composition of ethanol and glycerol monolaurate.
Transdermal administration of steroid drugs:
U.S. Patent Nos. 4,379,454, 4,460,372, 4,559,222, 4,568,343 (cited above with respect to the use of PEGML
as a permeation enhancer) and European Patent Publication No. 285563 relate to the transdermal administration of estrogens, while U.S. Patent No.
4,435,180 provides an example (Example IV at col. 7) which describes a system for the transdermal administration of progesterone. Concurrent administration of progesterone and estradiol esters is described in U.S. Patent No. 4,788,062. PCT Publication WO88/01496 and European Patent Publication No. 275716 both describe transdermal administration of a composition containing both an estrogen and a progestogen. In addition, European Patent Publication No. 235090 relates to the transdermal administration of an ethinyl estradiol/norethindrone acetate composition, while European Patent Publication No. 279982 describes a transdermal delivery system for the concurrent administration of ethinyl estradiol and levonorgestrel.
U.S. Patent No. 4,746,515, cited above as describing the use of GML as a permeation enhancer, also relates to the transdermal administration of steroid drugs. U.S.
Patent No. 4,704,282 relates to a transdermal drug delivery system for the administration of progesterone, testosterone and hydrocortisone. Other patents which relate to transdermal drug delivery devices stated to be useful in the administration of steroid drugs include U.S. Patent Nos.: 3,598,122; 3,598,123; 3,731,683;
3,797,494; 3,854,480; 3,923,939; 3,926,188; 3,964,482;
and 4,717,568.
Disclosure of the Invention Accordingly, it is an object of the present invention to provide a skin permeation enhancer composition comprising a first component that is an ether selected from the group consisting of diethylene glycol monoethyl ether and diethylene glycol monomethyl ether and a second component that is an ester given by the formula [CH3(CH2)mCOO]nR, in which m is an integer from 8 to 16, preferably 8 to 12, most preferably 10, n is 1 or 2, preferably 1, and R is a lower alkyl (Cl-C3) residue which may or may not be substituted with 1 or 2 hydroxyl groups.
It is another object of the present invention to provide a composition of matter useful for the delivery of a pharmacologically active agent through skin, comprising the above-described enhancer composition in combination with a selected pharmacologically active agent.
It is still another object of the invention to provide such a composition in which the pharmacologically active agent is a steroid drug.
It is a further object of the invention to provide methods and transdermal delivery systems for using the aforementioned compositions.
Additional objects, advantages and novel features of the invention will be set forth in part in the description which follows, and in part will become apparent to those skilled in the art upon examination of the following, or may be learned by practice of the invention.
In one aspect of the invention, a composition of matter is provided that is useful for the delivery of a pharmacologically active agent through the skin, comprising:
(a) a therapeutically effective amount of the at least one pharmacologically active agent; and (b) an amount of a permeation enhancer composition effective to enhance the penetration of the at least one pharmacologically active agent through skin, the enhancer composition comprising an ether component selected from the group consisting of diethylene glycol monoethyl ether and diethylene glycol monomethyl ether, and an ester component given by the formula ~CH3(CH2)mCOO]nR, in which m is an integer from 8 to 16, n is 1 or 2, and R is a lower alkyl (Cl-C3) residue which is either unsubstituted or substituted with one or two hydroxyl groups.
In another aspect of the invention, a method is provided that is useful for enhancing the skin penetration of a pharmacologically active agent, comprising applying to the skin, in addition to a therapeutically effective amount of the pharmacologically active agent, a permeation enhancer composition comprising an ether component selected from the group consisting of diethylene glycol monoethyl ether and diethylene glycol monomethyl ether, and an ester component given by the formula ~CH3(CH2)mCOO]nR, in which m, n and R are as defined above.
In still another aspect of the invention, a system is provided useful for the transdermal administration of a pharmacologically active agent, comprising:
(a) a source of the pharmacologically active agent;
(b) a source of a permeation enhancer composition comprising an ether component selected from 201287~
the group consisting of diethylene glycol monoethyl ether and diethylene glycol monomethyl ether, and an ester component given by the formula [CH3(CH2)mCOO]nR
with m, n and R as defined above; and S (c) a means for maintaining the system in agent and enhancer composition transmitting relationship to the skin.
Brief Description of the Fiqure Figure 1 is a graphic representation of the composition optimization results obtained in Example 6.
Modes for Carryinq Out the Invention "Penetration enhancement" or "permeation enhancement" as used herein relates to an increase in the permeability of skin to a pharmacologically active agent, i.e., so as to increase the rate at which the drug permeates through the skin and enters the bloodstream. The enhanced permeation effected through the use of such enhancers, and, in particular, through the use of the enhancer composition of the present invention, can be observed by measuring the rate of diffusion of drug through animal or human skin using a diffusion cell apparatus as described in the Examples herein By "transdermal" delivery, applicants intend to include both transdermal (or "percutaneous") and transmucosal administration, i.e., delivery by passage of a drug through the skin or mucosal tissue and into the bloodstream.
"Carriers" or "vehicles" as used herein refer to carrier materials suitable for transdermal drug administration, and include any such materials known in the art, e.g., any liquid, gel, solvent, liquid diluent, solubilizer, or the like, which is nontoxic and which does not interact with other components of the composition in a deleterious manner. Examples of suitable carriers for use herein include water, mineral oil, silicone, liquid sugars, waxes, petroleum jelly, and a variety of other oils and polymeric materials. In addition, one or both of the components of the present enhancer composition may also serve as a carrier.
By the term "pharmacologically active agent"
or "drug" as used herein is meant any chemical material or compound suitable for transdermal or transmucosal administration which induces a desired systemic effect.
Such substances include the broad classes of compounds normally delivered through body surfaces and membranes, including skin. In general, this includes: anti-infectives such as antibiotics and antiviral agents;
analgesics and analgesic combinations; anorexics;
antihelminthics; antiarthritics; antiasthmatic agents;
anticonvulsants; antidepressants; antidiabetic agents;
antidiarrheals; antihistamines; antiinflammatory agents;
antimigraine preparations; antinauseants;
antineoplastics; antiparkinsonism drugs; antipruritics;
antipsychotics; antipyretics; antispasmodics;
anticholinergics; sympathomimetics; xanthine deriva-tives; cardiovascular preparations including calcium channel blockers and beta-blockers such as pindolol and antiarrhythmics; antihypertensives; diuretics;
vasodilators including general coronary, peripheral and cerebral; central nervous system stimulants; cough and cold preparations, including decongestants; hormones such as estradiol and other steroids, including corticosteroids; hypnotics; immunosuppressives; muscle relaxants; parasympatholytics; psychostimulants;
sedatives; and tranquilizers.
Steroid drugs represent a preferred class of drugs for use in conjunction with the enhancer composition of the present invention. Examples of steroid drugs useful herein include: progestogens such 9 201287~
as norethindrone, norethindrone acetate, desogestrel, 3-keto desogestrel, gestadene and levonorgestrel estrogens such as estradiol and its esters, e.g., estradiol valerate, cyprionate, decanoate and acetate, as well as ethinyl estradiol; corticosteroids such as cortisone, hydrocortisone, fluocinolone acetonide; and testosterone. In a particularly preferred embodiment, the compositions of the invention include one or more estrogens as well as one or more progestogens.
By "therapeutically effective" amount of a pharmacologically active agent is meant a nontoxic but sufficient amount of a compound to provide the desired therapeutic effect. An "effective" amount of a permeation enhancer as used herein means an amount that will provide the desired increase in skin permeability and, correspondingly, the desired depth of penetration, rate of administration, and amount of drug delivered.
In a preferred embodiment, the enhancer composition of the invention contains a first, ether, component which is diethylene glycol monoethyl or monomethyl ether, and a second, ester, component given by the formula [CH3(CH2)mCOO]nR with m, n and R as defined above, wherein the preferred ratio (v/v) of the ether to the ester components in the enhancer composition ranges from about 90:10 to about 10:90, more preferably from about 90:10 to about 40:60. This ratio represents the relative amounts of the ether and ester components in the initial formulation of the enhancer composition. The preferred ratio may vary depending on whether-the enhancer composition is applied directly to the skin in an ointment, gel or the like, or whether it is incorporated into one or more layers of a transdermal drug delivery device. The preferred ratio may also vary with the specific components selected for the enhancer composition.
-lO- 20~87~
The ester component represented by the formula [CH3(CH2)mCOO]nR with m, n and R as above, contains 1 or 2, preferably 1, 10- to 18-carbon chains (i.e., wherein m is 8 to 16) bound to a central lower alkyl (Cl-C3) moiety which may be either unsubstituted or substituted with one or two hydroxyl groups. Thus, the component may include one or two capric, lauric, myristic, palmitic or stearic acid residues. In the preferred embodiment herein, the ester component is a lower alkyl (Cl-C3) laurate (i.e., m is 10 and n is 1), and in a particularly preferred case is "PGML". It will be appreciated by those skilled in the art that the commercially available material sold as "PGML" is typically a mixture of propylene glycol monolaurate itself, propylene glycol dilaurate, and either propylene glycol, methyl laurate, or both. Thus, the terms "PGML"
or "propylene glycol monolaurate" as used herein are intended to encompass both the pure compound as well as the mixture that is typically obtained commercially.
The present invention accordingly encompasses both the mixture of compounds which will typically be present in commercially available PGML, and as well as pure propylene glycol monolaurate itself.
In addition to the ester component, as noted above, the enhancer composition also contains diethylene glycol monoethyl or monomethyl ether, or both, preferably the monoethyl ether, i.e., Transcutol. While the ether and ester components have been sometimes referred to herein as the "first" and "second"
components, it will be appreciated by those skilled in the art that the composition may contain both the monoethyl and monomethyl ether, and may in addition include more than one ester component.
As will be established in the examples which follow, the combination of the ether and ester components increases the skin flux of a selected drug, generally, relative to the use of either type of component alone. (It should be noted, however, that the flux of a given drug through skin will vary with the drug or drugs selected for administration, the structure of the transdermal delivery device used, if any, and the vehicles incorporated into the drug-containing composition.) With certain drugs, one or both of the components may in addition act as a solubilizer or vehicle.
The composition may in addition include one or more selected carriers or excipients, and various agents and ingredients commonly employed in dermatological ointments and lotions. For examples, fragrances, opacifiers, preservatives, anti-oxidants, gelling agents, perfumes, thickening agents, stabilizers, surfactants, emollients, coloring agents, and the like may be present.
The relative amounts of the components in these compositions can vary a great deal. For example, the amount of drug or drugs present in the composition will depend on a variety of factors, including the disease to be treated, the nature and activity of the drug, the desired effect, possible adverse reactions, the ability and speed of the drug to reach its intended target, and other factors within the particular knowledge of the patient and physician. The amount of enhancer present in the composition will similarly depend on a number of factors, e.g., on the depth of cutaneous penetration desired, the strength of the particular enhancer, on the specific drug or drugs selected, and the like.
The method of delivery of the present compositions may also vary, but necessarily involves applying the selected composition to a defined surface of the skin or other tissue for a period of time sufficient to provide the desired blood level of drug for the desired period of time. The method may involve direct application of the composition as an ointment, gel, cream, or the like, or may involve use of a drug delivery device as taught, for example, in U.S. Patent Nos. 3,742,951, 3,797,494 or 4,568,343, and in commonly assigned U.S. Patent Application Serial No. 945,356, cited supra.
A transdermal delivery system can be constructed with the enhancer composition described hereinabove to deliver drugs for sustained drug delivery. The targeted skin flux for delivery of a particular drug can be achieved by adjusting vehicle composition and vehicle loading, as well as by adjusting the surface area through which the compositions are administered to skin.
Preferred transdermal drug delivery systems for use herein contain one or more drug/permeation enhancer reservoirs, a backing layer, and optionally one or more additional layers as those skilled in the art of transdermal drug delivery will readily appreciate.
The drug/permeation enhancer reservoir(s) will typically be in the the form of a matrix comprising rubber or other polymeric material, e.g., natural and synthetic rubbers such as polybutylene, polyisobutylene, polybutadiene, polyethylene, styrene-butadiene copolymers, polyisoprene, polyurethane, copolyesters, ethylene/acrylic copolymers, polyether amides, silicones and their copolymers, and butadiene/acrylonitrile copolymers, ethylene vinyl acetate, gelled or thickened mineral-oil, petroleum jelly and various aqueous gels and hydrophilic polymers that may serve as thickening agents. The matrix is applied to skin using a suitable adhesive as described, for example, in U.S. Patent No.
4,568,343, supra. In some cases, the matrix may itself be comprised of an adhesive material.
The drug reservoir layer is formulated so as to contain the selected pharmacologically active agent(s) as well as the above enhancer composition. In a preferred embodiment, the layer will contain up to about 15 wt.% drug (e.g., 5 wt.% estrogen, 10 wt.%
progestogen, in a preferred contraceptive patch), 5-40 wt.% enhancer composition, e.g., an 80:20 v/v Transcutol/PGML admixture, and up to 4 wt.% silicone oil or mineral oil to serve as a tackifier for the pressure-sensitive adhesive. The pressure sensitive adhesive which serves as the reservoir for this mixture is typically a polyisobutylene, silicone or acrylate adhesive. The layer may be formulated so that the selected drug is contained therein below saturation, at saturation, or in excess.
The backing membrane, which may be either occlusive or nonocclusive, is preferably comprised of a flexible, stretchable, polymer film, e.g., of polyether urethane, polyester urethane, polyamide, or other related copolymers. The material and thickness selected for the backing membrane is preferably such that a transdermal system can be provided having good wearability for at least a seven-day application.
It is to be understood that while the invention has been described in conjunction with the preferred specific embodiments thereof, that the foregoing description as well as the examples which follow are intended to illustrate and not limit the scope of the invention. Other aspects, advantages and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.
-14- 2~1287~
Example 1 In vitro Franz flow-through cells were used to compare the penetration of estradiol through skin using different ratios of Transcutol and methyl laurate. A
piece of human cadaver skin was mounted between the two half-cells and fastened with a clamp. Two hundred ~1 of saturated estradiol solutions (prepared with different ratios of Transcutol and methyl laurate, as indicated in Table 1) were applied to the donor compartment to start the experiment. The receiver compartment was filled with 0.1% gentamicin in distilled, deionized water and the temperature was maintained at 32~C. Samples were taken at preset time intervals and assayed by HPLC. The flux was calculated from the slope of the cumulative amounts of estradiol in the receiver compartment vs.
time. The results are summarized in Table 1. An increase in skin flux was observed when Transcutol was used in combination with methyl laurate at different ratios. The maximum flux (0.71 ~g/cm2/hr) was achieved when the ratio of Transcutol: methyl laurate was 80:20 (v/v) as compared to 0.36 and 0.35 ~g/cm2/hr when Transcutol or methyl laurate, respectively, were used alone.
201287~
Table 1 The effect of binary solutions with Transcutol and methyl laurate on the penetration of 5estradiol through human cadaver skin Vehicle composition Flux ( llg/cm2/hr ) Transcutol 0.35 + 0.19 Transcutol:methyl laurate0.71 i 0.03 (80:20, v/v) Transcutol:methyl laurate0.59 ~ 0.12 (60:gO, v/v) Transcutol:methyl laurate0.47 i 0.05 (40:60, v/v) Transcutol:methyl laurate0.46 i 0.14 (20:80, v/v) methyl laurate 0.36 + 0.16 The experiments were performed in triplicate for each vehicle combination.
20128~5 Example 2 The in vitro Franz flow-through cells were used to compare the penetration of estradiol through skin using different ratios of Transcutol in commercial PGML
(obtained from Gattefosse; approximate composition of this "PGML" was determined to be about 50 wt.% propylene glycol monolaurate itself, 40-45 wt.% propylene glycol dilaurate, and 5-10 wt.% propylene glycol). A piece of human cadaver skin was mounted between the two half-cells and fastened with a clamp. Two hundred ~1 of saturated estradiol solutions (prepared with different ratios of Transcutol and propylene glycol monolaurate, as indicated in Table 2) were applied to the donor compartment to start the experiment. The receiver compartment was filled with 0.1% gentamicin in distilled, deionized water and the temperature was maintained at 32~C. Samples were taken at preset time intervals and assayed by HPLC. The flux was calculated from the slope of the cumulative amounts of estradiol in the receiver compartment vs. time. The results are summarized in Table 2. The skin fluxes increase 2-3 fold when Transcutol was used in combination with propylene glycol monolaurate at different ratios. The flux reached a maximum value of 0.69 ~g/cm2/hr, when the ratio of Transcutol to PGML was about 80:20 (v/v). By contrast, fluxes of 0.37 and 0.21 ~g/cm2/hr were obtained for propylene glycol monolaurate and Transcutol, respectively, used alone.
Table 2 The effect of binary solutions with Transcutol and propylene glycol monolaurate on the penetration of estradiol through human cadaver skin Vehicle composition Flux ( ~lg/cm2/hr ) Transcutol 0.21 ~ 0.16 Transcutol:propylene glycol 0.69 + 0.12 monolaurate (80:20, v/v) Transcutol:propylene glycol 0.63 + 0.21 monolaurate (60:40, v/v) Transcutol:propylene glycol 0,49 i 0.14 monolaurate (40:60, v/v) Transcutol:propylene glycol 0.40 + 0.13 monolaurate (20:80, v/v) propylene glycol monolaurate 0.37 ~ 0.14 The experiments were performed in triplicate for each vehicle combination.
Example 3 The in vitro Franz flow-through cells were used to compare the penetration of norethindrone, norethindrone acetate and levonorgesterol in vehicles having different ratios of Transcutol and methyl laurate. A piece of human cadaver skin was mounted between the two half-cells and fastened with a clamp. Two hundred ~1 of saturated progestogens in solutions (prepared having different ratios of Transcutol and methyl laurate, as indicated in Table 3) were applied to the donor compartment to start the experiment. The receiver compartment was filled with 0.1% gentamycin in distilled, deionized water and the temperature was maintained at 32~C. Samples were taken at preset time interval and assayed by HPLC. The flux was calculated from the slope of the cumulative amounts of progestogens in the receiver compartment vs. time.
The skin fluxes for norethindrone, norethindrone acetate and levonorgesterol from vehicles with different ratios of Transcutol and methyl laurate are summarized in Table 3. The same trend, i.e., an increase in flux when Transcutol was used in combination with methyl laurate, was observed for these three progestogens. The maximum flux was again observed when the ratio of Transcutol to methyl laurate was about 80:20 (v/v). The maximum flux values obtained were 1.55, 1.71 and 0.25 ~g/cm2/hr for norethindrone, norethindrone acetate and levonorgesterol, respectively. In comparison, the fluxes for norethindrone, norethindrone acetate and levonorgesterol, with Transcutol alone, were 0.26, 0.63 and 0.09 ~g/cm2/hr, respectively, and, for methyl laurate alone, were 0.60, 1.03 and 0.12 ~g/cm2/hr. (It should also be noted that the 60:40 formulations gave slightly lower fluxes than for the 80:20 formulations, but were higher than that of either methyl laurate or Transcutol alone.) -lg- 201287 a a ~ ' O o o o o o ~ 1 o o o o o o ~ o ~ ,~, ,~ ~ ~
c ~'~ ~ ~ ~ ~ ~ ~ ~
~ L
~ a~
c C
E ~ ~ O _1 o --~ ~ ~ O O O O O O
,C ~ ~ ~+l +l ~ ~ ~ E
1 5 R 3 r ~ X ~ q u ~ C, Lo :-C O , U
c ~ . , o o o o o o o ~ ; ~ ~ ~ a u O ~~ ~D ~ ~1 ~J ~ I ~ ~ ~ . .
~, ~ o ~ l o o o a c Ll a o c a a ~ ~ e ~ o Ll Ll Ll Ll ~I
r 4I ~ I ~
v cc c c E e ~E ~E ~ E
o ~ ~C~
a u o o o u o ~ 4 ~ O O ~ O ~ O
Example 4 The in vitro Franz flow-through cells were used to compare the penetration of norethindrone, norethindrone acetate and levonorgesterol in vehicles containing varying amounts of Transcutol and propylene glycol mono-laurate. A piece of human cadaver skin was mounted between the two half-cells and fastened with a clamp.
Two hundred ~1 of saturated progestogen solutions (having varying ratios of Transcutol and propylene glycol monolaurate, as indicated in Table 4) were applied to the donor compartment to start the experi-ment. The receiver compartment was filled with 0.1%
gentamicin in distilled, deionized water and the temper-ature was maintained at 32~C. Samples were taken at preset time interval and assayed by HPLC. The flux was calculated from the slope of the cumulative amounts of progestogens in the receiver compartment vs. time.
The skin fluxes for norethindrone, norethindrone acetate and levonorgesterol from different ratios of Transcutol and PGML are summarized in Table 4. The same trend, i.e., increases in skin flux when Transcutol was used in combination with PGML, was observed for all three progestogens. The maximum flux for norethindrone was 0.79 ~g/cm2/hr, was observed when Transcutol was combined with propylene glycol monolaurate in an 80:20 (v/v) ratio, as compared to 0.17 and 0.31 for Transcutol and PGML alone, respectively. The maximum fluxes for norethindrone acetate were 1.31 to 1.33 ~g/cm2/hr when Transcutol was combined with PGML in 80:20 and 60:40 (v/v) ratios as compared to 0.26 and 0.39 for Transcutol and PGML alone. Similarly, the fluxes for levonorges-terol ranged from 0.06 to 0.09 ~g/cm2/hr when Transcutol was used in combination with PGML; the maximum flux was observed at a Transcutol:PGML ratio of 40:60 (v/v). By contrast, the fluxes, for levonorgesterol, were 0.02 and 0.06, respectively, using Transcutol and PGML alone.
--21 2 0 1 2 g 7 rj O ~ o o o o o o o o o o o o o o o o o o o o o o w - o c~ v _, o ,.
G ~
v a ~ L LJ ,, ~ ~ E a ~ o.
. u _~ ~ o ~ o o ._ o o o o o o C ~ ~
" ~ a ~ ~ x~ ~ ~ v ~" o, ~ , o ~ ~ o o ,~
O v ¢ O c ~' a ~ Z
,-, c n o ' f a u ~ . c O a~
,fa ,1 ~ ~ o O, O O O O
~, O , , ~
~- ~ L ~ a~ 1 U
O ~, ' t~ ~f,~ ~ ,,~ _ U tU ~ ~ ~ ~ ~ ~ ~
V " O
2 5 LV o I , C
U U U U E
~, ~ ~ ~ ~ O
~a~ v a c a c ~ c a a o ~ a ~ v u,o c o o c u o CL 8 ~ 8 r ~ .~ c --O O O O _1 ro ' o o o ~o' -22- 2~1 2~75 Example 5 A series of norethindrone acetate delivery systems was prepared by the following procedures. 2% of the norethindrone acetate (NA) was mixed and sonicated with various ratios of TC and PGML for 10 minutes.
Appropriate amounts of the drug-enhancer mixture were then added into a solution of silicone adhesive polymer (Dow Corning silicone #2675) in freon (50 wt.%) and rotated overnight. The drug-enhancer-polymer mixture was then cast on a polyester film (#1022 release liner) with a 8 mil knife. The solvent in the polymer system was evaporated in a 75~C oven for 15 min. The resulting polymer film was laminated with another polyester film (#1022).
Franz flow-through cells were used for in vitro skin flux experiments. The release liners were removed, and the polymer systems made were then laminated on stratum corneum of the human cadaver skin and mounted between the two half-cells and fastened with a clamp.
The receiver compartment was filled with 0.1% gentamicin in distilled, deionized water. The temperature was maintained at 32~C. Samples were taken every 8 hours for 3 days and assayed by HPLC. The flux was calculated from the slope of the cumulative amounts of norethindrone acetate in the receiver compartment vs.
time. The results of skin flux of norethindrone acetate in these polymer systems were tabulated in Table 5. The flux of norethindrone acetate from polymer systems was increased when Transcutol was used in combination with PGML, relative to Transcutol alone. The norethindrone acetate flux can also be increased by enhancer loading.
The flux increased from 0.17 to 0.75 ~g/cm2/hr when 20%
Transcutol/PGML (80:20, v/v) was incorporated into the polymer system instead of 5%. The flux was increased from 0.29 to 0.45 when 20% of the mixture was incorporated into the polymer instead of 5%.
Table 5 Flux of norethindrone acetate from a polymer matrix through human cadaver skin Vehicle Ratio Flux incorporated (NA:Vehicle:Sil.) (~g/cm2hr) TC 2:10:88 0.15 i 0.01 TC:PGML (80:20) 2:5:93 0.17 i 0.02 TC:PGML (80:20) 2:20:78 0.75 i 0.07 TC:PGML (50:50) 2:10:88 0.32 i 0.05 TC:PGML (20:80) 2:5:93 0.29 i 0.05 TC:PGML (20:80) 2:20:78 0.45 i 0.08 PGML 2:10:88 0.42 i 0.03 *Average i standard deviation; three experiments were performed for each vehicle combination.
-24- 201287~
Example 6 Optimization of the Transcutol/PGML Ratio: This study was designed as a matrix formulation step. It was conducted using Dow Corning silicone polymer #2675 as the matrix contact adhesive in which estradiol and TC/PGML were dispersed, with varying ratios of TC to PGML. The formulations tested are represented in Table 6.
Table 6 TC/PGML Enhancer Silicone Estradiol Ratio (v/v) (wt.%) (wt.%) (wt.%) 80:20 81 5 60:40 14% 81 5 40:60 81 5 80:20 75 5 60:40 20% 75 5 40:60 75 5 Methodoloqy: General in vitro skin methodology was as described in the preceding examples.
Skin permeation conditions: temperature, 32~C;
sampling times 7h, 17h, 24h, 48h; n=4. A static vertical Franz cell was used.
Skin preparation: pieces of skin recently excised (aesthetic surgery) prepared according to the method of Kligman.
Assay procedure: estradiol in the receptor compartment was assayed using HPLC at 210 nm using acetonitrile/TEAP buffer, pH 3.
Data analysis: estradiol skin fluxes were calculated by dividing the total amount of E2 permeated by the total duration of the experiment.
Matrices: matrices studied were fabricated with a hand-casting/solvent drying/hand-laminating general process. All matrices were allowed to equilibrate 8-10 days before skin permeation testing was begun.
Results and Discussion: The E2 skin flux values obtained with the different matrices are represented in Figure 1. The E2 fluxes were in the range of 0.06-0.2 ~g/cm2/hr for the different matrices tested. In a general way, the 20% loading gave higher fluxes than the 14% loading. For the two E2 loadings, 14% and 20%, there was a significant increase in E2 flux as the TC/PGML ratio decreased. With 14% loading, the highest flux was obtained with a TC/PGML ratio of 40:60, while with 20% loading, the highest flux was obtained with a TC/PGML ratio of 60:40.
This study permits one to conclude that the TC/PGML ratio should be optimized when the drug/enhancer composition is dispersed in a polymer medium.
Claims (11)
1. A composition of matter useful for the delivery of a pharmacologically active agent through the skin, comprising:
(a) a therapeutically effective amount of at least one pharmacologically active agent; and (b) an amount of a permeation enhancer composition effective to enhance the penetration of said at least one pharmacologically active agent through skin, the enhancer composition comprising an ether component selected from the group consisting of diethylene glycol monoethyl ether, diethylene glycol monomethyl ether, and a mixture thereof, and an ester component given by the formula [CH3(CH2) m COO]n R, in which m is an integer in the range of 8 to 16, n is 1 or 2, and R is a lower alkyl (C1-C3) residue that is either unsubstituted or substituted with one or two hydroxyl groups.
(a) a therapeutically effective amount of at least one pharmacologically active agent; and (b) an amount of a permeation enhancer composition effective to enhance the penetration of said at least one pharmacologically active agent through skin, the enhancer composition comprising an ether component selected from the group consisting of diethylene glycol monoethyl ether, diethylene glycol monomethyl ether, and a mixture thereof, and an ester component given by the formula [CH3(CH2) m COO]n R, in which m is an integer in the range of 8 to 16, n is 1 or 2, and R is a lower alkyl (C1-C3) residue that is either unsubstituted or substituted with one or two hydroxyl groups.
2. The composition of claim 1, wherein n is 10.
3. The composition of claims 1 or 2, wherein the ether component is diethylene glycol monoethyl ether.
4. The composition of claim 1, wherein the ether component is diethylene glycol monoethyl ether and the ester component comprises propylene glycol monolaurate or propylene glycol monolaurate in combination with propylene glycol dilaurate.
5. The composition of claim 1, wherein the at least one pharmacologically active agent is a steroid.
6. The composition of claim 1, wherein the at least one pharmacologically active agent comprises a progestogen, an estrogen, or a mixture thereof.
7. The composition of claim 6, wherein the progestogen is norethindrone or norethindrone acetate, and the estrogen is estradiol.
8. A system for the transdermal administration of at least one pharmacologically active agent, comprising:
(a) a source of the at least one pharmacologically active agent;
(b) a source of a permeation enhancer composition comprising an ether component selected from the group consisting of diethylene glycol monoethyl ether, diethylene glycol monomethyl ether, and mixtures thereof, and an ester component given by the formula [CH3(CH2) m COO]n R, in which m is an integer from 8 to 16, n is 1 or 2, and R is a lower alkyl (C1-C3) residue that is either unsubstituted or substituted with one or two hydroxyl groups; and (c) a means for maintaining the system in agent and enhancer composition transmitting relationship to the skin.
(a) a source of the at least one pharmacologically active agent;
(b) a source of a permeation enhancer composition comprising an ether component selected from the group consisting of diethylene glycol monoethyl ether, diethylene glycol monomethyl ether, and mixtures thereof, and an ester component given by the formula [CH3(CH2) m COO]n R, in which m is an integer from 8 to 16, n is 1 or 2, and R is a lower alkyl (C1-C3) residue that is either unsubstituted or substituted with one or two hydroxyl groups; and (c) a means for maintaining the system in agent and enhancer composition transmitting relationship to the skin.
9. The system of claim 8, wherein n is 10.
10. The system of claim 8, wherein the ether component is diethylene glycol monoethyl ether and the ester component is propylene glycol monolaurate or propylene glycol monolaurate in combination with propylene glycol dilaurate.
11. The system of claim 9, wherein the at least one pharmacologically active agent is a steroid.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US327,312 | 1989-03-22 | ||
| US07/327,312 US4973468A (en) | 1989-03-22 | 1989-03-22 | Skin permeation enhancer compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2012875A1 CA2012875A1 (en) | 1990-09-22 |
| CA2012875C true CA2012875C (en) | 1995-12-05 |
Family
ID=23276050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002012875A Expired - Fee Related CA2012875C (en) | 1989-03-22 | 1990-03-22 | Skin permeation enhancer compositions |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4973468A (en) |
| EP (1) | EP0464150B1 (en) |
| JP (1) | JP2550441B2 (en) |
| KR (1) | KR950010324B1 (en) |
| AT (1) | ATE156995T1 (en) |
| AU (1) | AU629331B2 (en) |
| CA (1) | CA2012875C (en) |
| DE (1) | DE69031309T2 (en) |
| DK (1) | DK0464150T3 (en) |
| ES (1) | ES2106029T3 (en) |
| FI (1) | FI914391A0 (en) |
| WO (1) | WO1990011064A1 (en) |
Families Citing this family (144)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5560922A (en) * | 1986-05-30 | 1996-10-01 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process |
| US5229129A (en) * | 1989-07-12 | 1993-07-20 | Cygnus Therapeutic Systems | Transdermal administration of lisuride |
| NZ237241A (en) * | 1990-03-02 | 1993-11-25 | Pharmetrix Corp | Method for increasing the storage stability of physostigmine |
| EP0523150A4 (en) * | 1990-04-06 | 1993-09-29 | Pharmetrix Corporation | Device and method for enhanced administration of physostigmine |
| US5225198A (en) * | 1991-08-27 | 1993-07-06 | Cygnus Therapeutic Systems | Transdermal administration of short or intermediate half-life benzodiazepines |
| US5518734A (en) * | 1991-09-25 | 1996-05-21 | Beta Pharmaceuticals Co. | Transdermal delivery system for estradiol and process for manufacturing said device |
| US5705185A (en) * | 1991-09-25 | 1998-01-06 | Beta Pharmaceuticals Co. | Transdermal delivery of estradiol and process for manufacturing said device |
| US5229130A (en) * | 1991-12-20 | 1993-07-20 | Cygnus Therapeutics Systems | Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems |
| US5453279A (en) * | 1992-04-21 | 1995-09-26 | Tbs Laboratories, Inc. | Enhancing transdermal absorption compositions; transdermal dosage form; and process |
| US6676967B1 (en) | 1993-09-20 | 2004-01-13 | Kos Pharmaceuticals, Inc. | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
| US6746691B2 (en) | 1993-09-20 | 2004-06-08 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
| US6818229B1 (en) | 1993-09-20 | 2004-11-16 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
| US6080428A (en) | 1993-09-20 | 2000-06-27 | Bova; David J. | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
| JPH0827003A (en) * | 1994-07-22 | 1996-01-30 | Sekisui Chem Co Ltd | Percutaneously absorbable pharmaceutical preparation |
| KR100382706B1 (en) | 1994-09-14 | 2003-10-10 | 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 | Matrix for transdermal drug delivery |
| GB9500116D0 (en) * | 1995-01-05 | 1995-03-01 | Ciba Geigy Ag | Pharmaceutical compositions |
| US5573778A (en) * | 1995-03-17 | 1996-11-12 | Adhesives Research, Inc. | Drug flux enhancer-tolerant pressure sensitive adhesive composition |
| US5882676A (en) * | 1995-05-26 | 1999-03-16 | Alza Corporation | Skin permeation enhancer compositions using acyl lactylates |
| US6572879B1 (en) * | 1995-06-07 | 2003-06-03 | Alza Corporation | Formulations for transdermal delivery of pergolide |
| DK1563788T3 (en) | 1995-08-29 | 2015-05-11 | Nitto Denko Corp | Microperforation of human skin for drug administration and monitoring purposes |
| DE19548332A1 (en) * | 1995-12-22 | 1997-07-10 | Rotta Res Bv | hormone patches |
| AU2036297A (en) * | 1996-03-20 | 1997-10-10 | Glaxo Group Limited | Topical formulations of aciclovir |
| IT1283102B1 (en) * | 1996-06-06 | 1998-04-07 | Permatec Nv | THERAPEUTIC COMPOSITION FOR THE TRANSDERMAL ADMINISTRATION OF AN ESTROGENIC OR PROGESTINIC ACTIVE SUBSTANCE OR OF THEIR MIXTURES |
| WO1998017315A2 (en) * | 1996-10-24 | 1998-04-30 | Alza Corporation | Permeation enhancers for transdermal drug delivery compositions, devices, and methods |
| CA2263334A1 (en) * | 1996-10-30 | 1998-05-07 | Sonal R. Patel | Fatty acid esters of lactic acid salts as permeation enhancers |
| KR100215027B1 (en) * | 1997-01-27 | 1999-08-16 | 성재갑 | Composition for transdermal administration of steroid drugs and formulation containing same |
| KR100294084B1 (en) * | 1998-06-02 | 2001-09-22 | 성재갑 | Composition for transdermal administration of non-steroid drugs and formulation containing same |
| US6572874B1 (en) * | 1998-05-15 | 2003-06-03 | Umd, Inc. | Vaginal delivery of bisphosphonates |
| IT1294748B1 (en) | 1997-09-17 | 1999-04-12 | Permatec Tech Ag | FORMULATION FOR A TRANSDERMAL DEVICE |
| US6414028B1 (en) * | 1997-11-05 | 2002-07-02 | Nexmed Holdings, Inc. | Topical compositions containing prostaglandin E1 |
| US6046244A (en) * | 1997-11-05 | 2000-04-04 | Nexmed Holdings, Inc. | Topical compositions for prostaglandin E1 delivery |
| WO1999032153A1 (en) | 1997-12-22 | 1999-07-01 | Alza Corporation | Monoglyceride and ethyl palmitate permeation enhancer compositions |
| DE19814084B4 (en) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's syndrome and process for its preparation |
| CA2326222C (en) * | 1998-04-27 | 2008-09-23 | Fujisawa Pharmaceutical Co., Ltd. | Medicinal compositions |
| FR2761600B1 (en) * | 1998-06-19 | 2000-03-31 | Oreal | FOAMING COMPOSITION FOR THE WASHING AND TREATMENT OF HAIR AND / OR SCALP BASED ON AN ACTIVE INGREDIENT, AN ANIONIC SURFACTANT, AN AMPHOTERIC SURFACTANT AND A PROPENETANT |
| GB9825402D0 (en) † | 1998-11-19 | 1999-01-13 | Pfizer Ltd | Antiparasitic formulations |
| US20030078499A1 (en) * | 1999-08-12 | 2003-04-24 | Eppstein Jonathan A. | Microporation of tissue for delivery of bioactive agents |
| USRE44145E1 (en) | 2000-07-07 | 2013-04-09 | A.V. Topchiev Institute Of Petrochemical Synthesis | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
| US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| ATE485837T1 (en) * | 2000-08-03 | 2010-11-15 | Antares Pharma Ipl Ag | COMPOSITION FOR TRANSDERMAL AND/OR TRANSMUCOSAL ADMINISTRATION OF ACTIVE INGREDIENTS WHICH GUARANTEES ADEQUATE THERAPEUTIC LEVELS |
| US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
| US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
| DE10041478A1 (en) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | New pharmaceutical composition |
| DE60239528D1 (en) | 2001-05-01 | 2011-05-05 | Corium International Redwood City | TWO-PHASE, WATER-ABSORBING BIOADHESIVE COMPOSITION |
| JP4116447B2 (en) | 2001-05-01 | 2008-07-09 | エイ．ブイ．トップチーブ インスティテュート オブ ペトロケミカル シンセシス | Hydrogel composition |
| US20050113510A1 (en) | 2001-05-01 | 2005-05-26 | Feldstein Mikhail M. | Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components |
| US8206738B2 (en) | 2001-05-01 | 2012-06-26 | Corium International, Inc. | Hydrogel compositions with an erodible backing member |
| US8840918B2 (en) | 2001-05-01 | 2014-09-23 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
| US8541021B2 (en) | 2001-05-01 | 2013-09-24 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
| US20050215727A1 (en) | 2001-05-01 | 2005-09-29 | Corium | Water-absorbent adhesive compositions and associated methods of manufacture and use |
| DK1450804T3 (en) * | 2001-11-29 | 2009-01-05 | 3M Innovative Properties Co | Pharmaceutical formula rings comprising an immune response modifier |
| DE10159120B4 (en) * | 2001-12-01 | 2006-08-17 | Lts Lohmann Therapie-Systeme Ag | Steroid hormone-containing transdermal therapeutic systems containing propylene glycol monocaprylate and its use |
| US20040033253A1 (en) * | 2002-02-19 | 2004-02-19 | Ihor Shevchuk | Acyl opioid antagonists |
| ES2612779T3 (en) * | 2002-03-11 | 2017-05-18 | Nitto Denko Corporation | System of transdermal patches of drug administration, method of manufacture thereof and method of use thereof |
| US8116860B2 (en) * | 2002-03-11 | 2012-02-14 | Altea Therapeutics Corporation | Transdermal porator and patch system and method for using same |
| US9918665B2 (en) | 2002-03-11 | 2018-03-20 | Nitto Denko Corporation | Transdermal porator and patch system and method for using same |
| US20030199584A1 (en) * | 2002-04-11 | 2003-10-23 | Ahluwalia Gurpreet S. | Reduction of hair growth |
| DE10234673B4 (en) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Hot-melt TTS for the administration of rotigotine and process for its preparation, and use of rotigotine in the manufacture of a hot-melt TTS |
| US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
| US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
| US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
| WO2004017941A2 (en) * | 2002-08-20 | 2004-03-04 | Euro-Celtique, S.A. | Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist |
| EP1556501A4 (en) | 2002-10-28 | 2009-04-08 | Transform Pharmaceuticals Inc | Transdermal assay with magnetic clamp |
| EP1426049B1 (en) * | 2002-12-02 | 2005-05-18 | Schwarz Pharma Ag | Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease |
| CA2453013C (en) * | 2002-12-13 | 2011-02-15 | Gary W. Cleary | Dermal, transdermal, mucosal or transmucosal ingredient delivery devices |
| JP4542743B2 (en) * | 2002-12-26 | 2010-09-15 | Ｋｄｌ株式会社 | Solution pharmaceutical composition of pyridone derivatives |
| DE10261696A1 (en) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Device for the transdermal administration of rotigotine base |
| US7858607B2 (en) * | 2003-03-14 | 2010-12-28 | Mamchur Stephen A | System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer |
| US20040241223A1 (en) * | 2003-05-27 | 2004-12-02 | David Wong | Oral dosage forms for macromolecular drugs |
| US7816546B2 (en) * | 2003-06-30 | 2010-10-19 | Richter Gedeon Vegyeszeti Gyar Rt. | Process for the synthesis of high purity d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-oxime |
| WO2005007020A2 (en) | 2003-07-03 | 2005-01-27 | Corium International, Inc. | Wound dressing, ingredient delivery device and iv hold-down, and method relating to same |
| US20080020028A1 (en) * | 2003-08-20 | 2008-01-24 | Euro-Celtique S.A. | Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent |
| MXPA06003316A (en) * | 2003-10-10 | 2006-06-08 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues. |
| US8016811B2 (en) | 2003-10-24 | 2011-09-13 | Altea Therapeutics Corporation | Method for transdermal delivery of permeant substances |
| US7105263B2 (en) * | 2003-12-30 | 2006-09-12 | Samsung Electronics Company | Dry toner comprising encapsulated pigment, methods and uses |
| CA2554649C (en) | 2004-01-30 | 2015-10-27 | Corium International, Inc. | Rapidly dissolving film for delivery of an active agent |
| WO2005077364A1 (en) * | 2004-02-18 | 2005-08-25 | Yamanouchi Pharmaceutical Co., Ltd. | Transdermal solifenacin preparation and method of improving transdermal permeability thereof |
| US7425340B2 (en) * | 2004-05-07 | 2008-09-16 | Antares Pharma Ipl Ag | Permeation enhancing compositions for anticholinergic agents |
| US20060008432A1 (en) * | 2004-07-07 | 2006-01-12 | Sebastiano Scarampi | Gilsonite derived pharmaceutical delivery compositions and methods: nail applications |
| BRPI0513279A (en) * | 2004-07-15 | 2008-05-06 | Freedom 2 Llc | modified fabric marking pigment and method for modifying fabric marking pigment |
| JP5270158B2 (en) | 2004-08-05 | 2013-08-21 | コリウム インターナショナル， インコーポレイテッド | Adhesive composition |
| EP1853560A1 (en) | 2005-02-23 | 2007-11-14 | Psychenomics, Inc. | Dopamine transporter inhibitors for use in treatment of movement disorders and other cns indications |
| WO2007124250A2 (en) | 2006-04-21 | 2007-11-01 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
| US8067399B2 (en) | 2005-05-27 | 2011-11-29 | Antares Pharma Ipl Ag | Method and apparatus for transdermal or transmucosal application of testosterone |
| US20070065494A1 (en) * | 2005-08-03 | 2007-03-22 | Watson Laboratories, Inc. | Formulations and Methods for Enhancing the Transdermal Penetration of a Drug |
| US10137135B2 (en) * | 2005-08-15 | 2018-11-27 | Allergan Sales, Llc | Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith |
| DE102006050558B4 (en) | 2006-10-26 | 2009-03-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing norelgestromin for contraception and hormone replacement |
| EP2182987A4 (en) * | 2007-07-30 | 2011-11-02 | Medacure International Inc | Immune system modulator formulation |
| US20090098191A1 (en) * | 2007-10-16 | 2009-04-16 | Anderson Christopher G | Use of bases to stabilize transdermal formulations |
| US8609733B2 (en) * | 2008-05-19 | 2013-12-17 | Massachusetts Institute Of Technology | Sensory-specific local anesthesia and prolonged duration local anesthesia |
| US8658699B2 (en) * | 2008-05-19 | 2014-02-25 | Massachusetts Institute Of Technology | Chemical permeation enhancers enhance nerve blockade by toxins |
| WO2010083035A2 (en) | 2009-01-14 | 2010-07-22 | Corium International, Inc. | Transdermal administration of tamsulosin |
| US9119578B2 (en) | 2011-04-29 | 2015-09-01 | Seventh Sense Biosystems, Inc. | Plasma or serum production and removal of fluids under reduced pressure |
| US9295417B2 (en) | 2011-04-29 | 2016-03-29 | Seventh Sense Biosystems, Inc. | Systems and methods for collecting fluid from a subject |
| US9041541B2 (en) | 2010-01-28 | 2015-05-26 | Seventh Sense Biosystems, Inc. | Monitoring or feedback systems and methods |
| JP6078230B2 (en) | 2009-03-02 | 2017-02-08 | セブンス センス バイオシステムズ，インコーポレーテッド | Techniques and devices related to blood sampling |
| WO2010101625A2 (en) | 2009-03-02 | 2010-09-10 | Seventh Sense Biosystems, Inc. | Oxygen sensor |
| US9033898B2 (en) | 2010-06-23 | 2015-05-19 | Seventh Sense Biosystems, Inc. | Sampling devices and methods involving relatively little pain |
| US8957207B2 (en) | 2009-03-24 | 2015-02-17 | Proteus S.A. | Methods for producing phycotoxins |
| WO2011000210A1 (en) * | 2009-07-01 | 2011-01-06 | 润和生物医药科技(汕头)有限公司 | Composition of permeation enhancer and use thereof in transdermal drug delivery system |
| AU2010279384A1 (en) | 2009-08-05 | 2012-03-01 | Wake Forest University | Compositions and methods for inducing apoptosis in prostate cancer cells |
| JP6022442B2 (en) | 2010-05-14 | 2016-11-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Male contraceptive compositions and methods of use |
| US20120016308A1 (en) | 2010-07-16 | 2012-01-19 | Seventh Sense Biosystems, Inc. | Low-pressure packaging for fluid devices |
| US20130158482A1 (en) | 2010-07-26 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Rapid delivery and/or receiving of fluids |
| WO2012021801A2 (en) | 2010-08-13 | 2012-02-16 | Seventh Sense Biosystems, Inc. | Systems and techniques for monitoring subjects |
| EP2992827B1 (en) | 2010-11-09 | 2017-04-19 | Seventh Sense Biosystems, Inc. | Systems and interfaces for blood sampling |
| US20130158468A1 (en) | 2011-12-19 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving material with respect to a subject surface |
| EP2701600B1 (en) | 2011-04-29 | 2016-06-08 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving fluids |
| WO2013027840A1 (en) * | 2011-08-25 | 2013-02-28 | ニプロパッチ株式会社 | Hydrous adhesive skin patch |
| DE102011119043A1 (en) | 2011-11-22 | 2013-05-23 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermal therapeutic system comprises an active substance-impermeable backing layer, self-adhesive reservoir with content of active substance, which is rotigotine or rotigotine derivative, and a removable protective layer |
| WO2013078422A2 (en) | 2011-11-23 | 2013-05-30 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| AU2013211876B2 (en) * | 2012-01-26 | 2017-02-09 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10258682B2 (en) | 2013-01-16 | 2019-04-16 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Attenuated chlamydia vaccine |
| KR20150131330A (en) | 2013-03-15 | 2015-11-24 | 더 칠드런스 메디칼 센터 코포레이션 | neosaxitoxin combination formulations for prolonged local anesthesia |
| AU2014251207B2 (en) | 2013-04-07 | 2019-06-13 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
| US20160287549A1 (en) | 2013-11-22 | 2016-10-06 | Genzyme Corporation | Novel methods for treating neurodegenerative diseases |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| CN106456724A (en) | 2013-12-20 | 2017-02-22 | 博德研究所 | Combination therapy with neoantigen vaccine |
| US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| MX2016013693A (en) | 2014-07-29 | 2017-10-31 | Therapeuticsmd Inc | Transdermal cream. |
| US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
| EP3234193B1 (en) | 2014-12-19 | 2020-07-15 | Massachusetts Institute of Technology | Molecular biomarkers for cancer immunotherapy |
| IL255769B2 (en) | 2015-05-20 | 2023-09-01 | Broad Inst Inc | Shared neoantigens |
| WO2017004507A1 (en) * | 2015-07-02 | 2017-01-05 | Noven Pharmaceuticals, Inc. | Transdermal drug delivery systems for levonorgestrel and ethinyl estradiol |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US20190346442A1 (en) | 2016-04-18 | 2019-11-14 | The Broad Institute, Inc. | Improved hla epitope prediction |
| US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3551554A (en) * | 1968-08-16 | 1970-12-29 | Crown Zellerbach Corp | Enhancing tissue penetration of physiologically active agents with dmso |
| US3472931A (en) * | 1969-01-17 | 1969-10-14 | Foster Milburn Co | Percutaneous absorption with lower alkyl amides |
| US3598122A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3854480A (en) * | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3797494A (en) * | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
| US3964482A (en) * | 1971-05-17 | 1976-06-22 | Alza Corporation | Drug delivery device |
| US3731683A (en) * | 1971-06-04 | 1973-05-08 | Alza Corp | Bandage for the controlled metering of topical drugs to the skin |
| US3742951A (en) * | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
| US3923989A (en) * | 1973-07-13 | 1975-12-02 | Sandoz Ag | Nitro substituted picolinonitriles as anti-bacterial and anti-fungal agents |
| US4006218A (en) * | 1974-07-08 | 1977-02-01 | Johnson & Johnson | Potentiated medicaments |
| US3926188A (en) * | 1974-11-14 | 1975-12-16 | Alza Corp | Laminated drug dispenser |
| US3989816A (en) * | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4316893A (en) * | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US4405616A (en) * | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US4460372A (en) * | 1981-02-17 | 1984-07-17 | Alza Corporation | Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer |
| US4379454A (en) * | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
| US4440771A (en) * | 1982-02-12 | 1984-04-03 | The United States Of America As Represented By The Secretary Of The Army | 2-Acetyl quinoline thiosemicarbazones useful in treatment of gonorrhea, malaria or bacterial infections |
| US4435180A (en) * | 1982-05-25 | 1984-03-06 | Alza Corporation | Elastomeric active agent delivery system and method of use |
| FR2542998B1 (en) * | 1983-03-24 | 1986-01-31 | Rhone Poulenc Sante | NEW TRANSDERMAL FORM OF ISOSORBIDE DINITRATE |
| US4559222A (en) * | 1983-05-04 | 1985-12-17 | Alza Corporation | Matrix composition for transdermal therapeutic system |
| US4552872A (en) * | 1983-06-21 | 1985-11-12 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing corticosteroids |
| US4557934A (en) * | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
| US4537776A (en) * | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
| US4704282A (en) * | 1984-06-29 | 1987-11-03 | Alza Corporation | Transdermal therapeutic system having improved delivery characteristics |
| US4568343A (en) * | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
| US4818540A (en) * | 1985-02-25 | 1989-04-04 | Rutgers, The State University Of New Jersey | Transdermal fertility control system and process |
| US4717568A (en) * | 1985-08-09 | 1988-01-05 | Alza Corporation | Laminar arrangement for increasing delivery of beneficial agent from dispenser |
| ZA87332B (en) * | 1986-02-27 | 1987-08-26 | Warner Lambert Co | Compositions containing fixed combinations |
| US4908389A (en) * | 1986-08-27 | 1990-03-13 | Warner-Lambert Company | Penetration enhancement system |
| AU601528B2 (en) * | 1986-12-22 | 1990-09-13 | Ortho-Mcneil Pharmaceutical, Inc. | Resilient transdermal drug-delivery device and compositions and devices employing fatty acid esters/ethers of alkanediols and percutaneous absorption enhancers |
| CN1021196C (en) * | 1986-12-29 | 1993-06-16 | 新泽西州州立大学(鲁杰斯) | Prepn. method of progestin unit and system |
| US4788062A (en) * | 1987-02-26 | 1988-11-29 | Alza Corporation | Transdermal administration of progesterone, estradiol esters, and mixtures thereof |
| US4746515A (en) * | 1987-02-26 | 1988-05-24 | Alza Corporation | Skin permeation enhancer compositions using glycerol monolaurate |
| US4816258A (en) * | 1987-02-26 | 1989-03-28 | Alza Corporation | Transdermal contraceptive formulations |
| CH674618A5 (en) * | 1987-04-02 | 1990-06-29 | Ciba Geigy Ag | |
| US4783450A (en) * | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
| US4764379A (en) * | 1987-08-24 | 1988-08-16 | Alza Corporation | Transdermal drug delivery device with dual permeation enhancers |
-
1989
- 1989-03-22 US US07/327,312 patent/US4973468A/en not_active Expired - Lifetime
-
1990
- 1990-03-19 AT AT90905963T patent/ATE156995T1/en not_active IP Right Cessation
- 1990-03-19 AU AU54174/90A patent/AU629331B2/en not_active Ceased
- 1990-03-19 KR KR1019910701172A patent/KR950010324B1/en not_active IP Right Cessation
- 1990-03-19 DE DE69031309T patent/DE69031309T2/en not_active Expired - Lifetime
- 1990-03-19 WO PCT/US1990/001469 patent/WO1990011064A1/en active IP Right Grant
- 1990-03-19 DK DK90905963.6T patent/DK0464150T3/en active
- 1990-03-19 EP EP90905963A patent/EP0464150B1/en not_active Expired - Lifetime
- 1990-03-19 JP JP2505844A patent/JP2550441B2/en not_active Expired - Lifetime
- 1990-03-19 ES ES90905963T patent/ES2106029T3/en not_active Expired - Lifetime
- 1990-03-22 CA CA002012875A patent/CA2012875C/en not_active Expired - Fee Related
-
1991
- 1991-09-18 FI FI914391A patent/FI914391A0/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69031309D1 (en) | 1997-09-25 |
| WO1990011064A1 (en) | 1990-10-04 |
| AU629331B2 (en) | 1992-10-01 |
| JP2550441B2 (en) | 1996-11-06 |
| CA2012875A1 (en) | 1990-09-22 |
| KR920700601A (en) | 1992-08-10 |
| DK0464150T3 (en) | 1997-09-15 |
| EP0464150B1 (en) | 1997-08-20 |
| DE69031309T2 (en) | 1998-01-08 |
| JPH04505157A (en) | 1992-09-10 |
| AU5417490A (en) | 1990-10-22 |
| US4973468A (en) | 1990-11-27 |
| ES2106029T3 (en) | 1997-11-01 |
| KR950010324B1 (en) | 1995-09-14 |
| FI914391A0 (en) | 1991-09-18 |
| EP0464150A1 (en) | 1992-01-08 |
| EP0464150A4 (en) | 1993-04-14 |
| ATE156995T1 (en) | 1997-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2012875C (en) | Skin permeation enhancer compositions | |
| US5059426A (en) | Skin permeation enhancer compositions, and methods and transdermal systems associated therewith | |
| US5053227A (en) | Skin permeation enhancer compositions, and methods and transdermal systems associated therewith | |
| US5229130A (en) | Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems | |
| EP0910353B1 (en) | Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents | |
| CA2135925C (en) | Use of glycerin in moderating transdermal drug delivery | |
| US5641504A (en) | Skin permeation enhancer compositions using glycerol monolinoleate | |
| CA2217888C (en) | Triacetin as a transdermal penetration enhancer | |
| EP0835136B1 (en) | Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate | |
| US5378730A (en) | Permeation enhancer comprising ethanol and monoglycerides | |
| US4900555A (en) | Skin permeation enhancer compositions using sucrose esters | |
| US4940586A (en) | Skin permeation enhancer compositions using sucrose esters | |
| US5227169A (en) | Sorbitan esters as skin permeation enhancers | |
| EP0744944A1 (en) | Sexual steroid-containing transdermal therapeutic systems | |
| WO1992020377A1 (en) | Skin permeation enhancer compositions using glycerol monolinoleate | |
| AU3771689A (en) | Permeation enhancer comprising ethanol and glycerol monooleate | |
| WO1995005137A1 (en) | Transdermal delivery system using a combination of permeation enhancers | |
| WO1997009971A2 (en) | High capacity, superabsorbent drug reservoirs for use in transdermal drug delivery systems | |
| IE921615A1 (en) | Skin permeation enhancer compositions using glycerol¹monolinoleate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |